Sarcoma Drugs Market Thumbnail Image

2022

Sarcoma Drugs Market

Sarcoma Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Disease Indication, by Treatment, by End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

LS : Pharmaceuticals

Select an option
Author's: Linu Dash | Roshan Deshmukh
Publish Date:

Get Sample to Email

Sarcoma Drugs Market Research, 2031

The global sarcoma drugs market size was valued at $1,127.0 million in 2021 and is projected to reach $2,497.1 million by 2031, growing at a CAGR of 8.3% from 2022 to 2031. Sarcoma is a form of cancer that can appear anywhere on your body. A large range of tumors that start in the bones and soft tissues are collectively referred to as sarcomas, commonly known as soft tissue sarcomas. The tissues that join, encircle, and support other body structures are where soft tissue sarcomas develop. This comprises your muscle, fat, blood vessels, nerves, tendons, and joint lining. Sarcomas come in over 70 different varieties. The type, location, and other aspects of the sarcoma will all affect how it is treated. The disease indication for use of sarcoma drugs includes malignant bone tumors and soft tissue sarcoma. Soft tissue sarcoma includes dermatofibrosarcoma, leiomyosarcoma, synovial cell sarcoma, rhabdomyosarcoma and others. In the treatment for sarcoma includes such chemotherapy, targeted drug therapy and others. End user of sarcoma drugs are hospitals and clinics and cancer research center.

Growth of the global sarcoma drugs market size is majorly driven by rise in the prevalence of soft tissue sarcoma and rise in the awareness among the people regarding soft tissue sarcoma. Sarcoma is a form of cancer. It can affect different types of tissue. Soft tissue sarcomas affect tissues connecting, supporting, or surrounding any of the body’s systems. According to the American Society of Clinical Oncology (ASCO), it accounts for around 1% of all adult cancers. It is more common in children, accounting for around 15% of all childhood cancers. Moreover, according to the National Cancer Institute, it was estimated that, doctors in the U.S. will diagnose around 12,750 cases of soft tissue sarcoma in 2019, and they predict that 5,270 people will die from a sarcoma. In addition, according to American Cancer Society, it was estimated that, 3,600 bone and joint new cancer cases were diagnosed in 2020. Among them 2,120 are male and 1,480 are female in U.S. As per the same source, approximately 1,720 deaths were estimated in U.S. in 2020 due to bone and joint cancer. Moreover, according to the American Cancer Society, in 2022, it was estimated that about 13,190 new soft tissue sarcomas will be diagnosed, among them 7,590 in males and 5,600 in females in the U.S. As per the same source, it was estimated that, about 5,130 people (2,740 males and 2,390 females) are expected to die of soft tissue sarcomas

Sarcoma Drugs Market

Moreover, rise in the number of product approval for new sarcoma drugs attribute to boost the sarcoma drugs market growth. For instance, in May 2020, Bristol Myers Squibb, a pharmaceutical company, announced the approval of Pomalyst (pomalidomide). It was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV-negative.

In addition, rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by sarcoma drugs industry fuels the growth of market For instance, in March 2021, Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform,  announced it has entered into a clinical development collaboration with AgonOx, Inc. to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL based product candidate PH-762 and AgonOx's "double positive" (DP) tumor-infiltrating lymphocyte (TIL) technology.

On the other hand, side effects and high cost of chemotherapy are anticipated to restrain the growth sarcoma drugs market.  

Sarcoma Drugs Market Segmentation

The global sarcoma drugs market share is segmented on the basis of disease indication, treatment, end user and region. On the basis of type the market is segmented into malignant bone tumors and soft tissue sarcoma. Soft tissue sarcoma is further sub-segmented into dermatofibrosarcoma, leiomyosarcoma, synovial cell sarcoma, rhabdomyosarcoma and others. On the basis of treatment market is segmented into chemotherapy and targeted drug therapy. On the end user, market is bifurcated into hospitals and clinics and cancer research center. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

Sarcoma Drugs Market By Disease Indication

On the basis of disease indication, the market is classified into malignant bone tumors and soft tissue sarcoma. The soft tissue sarcoma segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to increase in the awareness among the people regarding soft tissue sarcoma and rise in the prevalence of soft tissue sarcoma.

Sarcoma Drugs Market by Disease Indication

Sarcoma Drugs Market By Treatment

On the basis of treatment, it is classified into chemotherapy, targeted drug therapy and others. The chemotherapy segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to increase in the awareness among the people regarding chemotherapy and rise in number of product launch for chemotherapy.

Sarcoma Drugs Market by Treatment

Sarcoma Drugs Market By End User

On the basis of end user, the market is classified into hospitals & clinics and cancer research center. The hospitals and clinics segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to rise in expenditure by government to develop healthcare sector.

Sarcoma Drugs Market by End User

North America accounted for a majority of the global sarcoma drugs market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to increase in the number of research activities, technological advancement in the healthcare sector and rise in the prevalence of soft tissue sarcoma. Asia-Pacific is anticipated to witness lucrative growth, owing to owing rise in expenditure by government organization to develop healthcare sector, increase in prevalence of cancer and rise in the number of sarcoma drugs industry.         

Sarcoma Drugs Market by Region

Some of the major companies that operate in the global sarcoma drugs market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Hoffmann-La Roche AG., Daiichi Sankyo Company, Limited., AgonOX, Inc. and Eisai Co., Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sarcoma drugs market analysis from 2021 to 2031 to identify the prevailing sarcoma drugs market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the sarcoma drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global sarcoma drugs market trends, key players, market segments, application areas, and market growth strategies.

Sarcoma Drugs Market Report Highlights

Aspects Details
icon_1
Market Size By 2031

USD 2.5 billion

icon_2
Growth Rate

CAGR of 8.3%

icon_3
Forecast period

2021 - 2031

icon_4
Report Pages

220

icon_5
By Disease Indication
  • Malignant bone tumors
  • Soft tissue sarcoma
    • Type
      • Dermatofibro sarcoma
      • Leiomyosarcoma
      • Synovial cell sarcoma
      • Rhabdomyo sarcoma
      • Others
icon_6
By Treatment
  • Chemotherapy
  • Targeted drug therapy
icon_7
By End User
  • Hospital and clinics
  • Cancer research center
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_9
Key Market Players

AgonOX, Inc., BRISTOL-MYERS SQUIBB COMPANY, Johnson and Johnson, Eisai Co., Ltd., MERCK & CO., INC., Hoffmann-La Roche AG., Novartis AG, Baxter Healthcare Corporation, Daiichi Sankyo Company, Limited, GlaxoSmithKline, plc.

Analyst Review

A sarcoma is a malignant tumor, a type of cancer that arises from transformed cells of mesenchymal (connective tissue) origin. Medical conditions such as malignant bone tumors, soft tissue sarcoma require chemotherapy and targeted therapy for treatment. The sarcoma drugs market is expected to grow during the forecast period, owing to rise in the prevalence of soft tissue sarcoma, increase in the number of product launch and product approval for sarcoma drugs and technological advancement in chemotherapy and targeted therapy.

Rise in adoption of key strategies such as collaboration, acquisition, agreement, and partnership by key players of sarcoma drugs fuels growth of the market. For instance, in March 2021, Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform announced it has entered into a clinical development collaboration with AgonOx, Inc. to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL based product candidate PH-762 and AgonOx's "double positive" (DP) tumor-infiltrating lymphocyte (TIL) technology.

In addition, rise in number of product approvals for new technologies fuels the market growth. For instance, in May 2020, Bristol Myers Squibb, a pharmaceutical company, announced the approval of Pomalyst (pomalidomide). It was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV-negative.

Author Name(s) : Linu Dash | Roshan Deshmukh
Frequently Asked Questions?

The total market value of sarcoma drugs market is $1,127 million in 2021.

The forecast period in the report is from 2022 to 2031

The market value of sarcoma drugs market in 2022 was $1,217.2 million

The base year for the report is 2021.

Yes, sarcoma drugs companies are profiled in the report

The top companies that hold the market share in sarcoma drugs market are Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Hoffmann-La Roche AG., Daiichi Sankyo Company, Limited., AgonOX, Inc. and Eisai Co., Ltd

Asia-Pacific is expected to register highest from 2022 to 2031, owing to rise in expenditure by government organization to develop healthcare sector, increase in prevalence of cancer and rise in the number of key players who manufactures sarcoma drugs

The key trends in the sarcoma drugs market are rise in the prevalence of soft tissue sarcoma and rise in the awareness among the people regarding soft tissue sarcoma

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Sarcoma Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021-2031